gefitinib has been researched along with u 73122 in 2 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (u 73122) | Trials (u 73122) | Recent Studies (post-2010) (u 73122) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 1,252 | 2 | 236 |
| Protein | Taxonomy | gefitinib (IC50) | u 73122 (IC50) |
|---|---|---|---|
| Telomerase reverse transcriptase | Homo sapiens (human) | 0.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, MS; Kim, SH; Yang, SH | 1 |
| Joseph, AM; Kamath, A; Mittal, S; Rajala, MS | 1 |
2 other study(ies) available for gefitinib and u 73122
| Article | Year |
|---|---|
Restricting extracellular Ca2+ on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca2+ response, which consequently enhances gefitinib sensitivity.
Topics: Antineoplastic Agents; Calcium Signaling; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Estrenes; Gefitinib; Humans; Lung Neoplasms; NFATC Transcription Factors; Pyrrolidinones; Type C Phospholipases | 2020 |
PLCγ1‑dependent invasion and migration of cells expressing NSCLC‑associated EGFR mutants.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Movement; Cell Proliferation; ErbB Receptors; Estrenes; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Invasiveness; Phosphodiesterase Inhibitors; Phospholipase C gamma; Protein Kinase Inhibitors; Pyrrolidinones; Recombinant Proteins; Signal Transduction | 2020 |